1-8 of 8
pcsk9 gene
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effect of Loss-of-Function Genetic Variants in PCSK9 on Glycemic Traits, Neurocognitive Impairment, and Hepatobiliary Function

Jonas Ghouse, Gustav Ahlberg, Henning Bundgaard, Morten S. Olesen
Journal: Diabetes Care
Diabetes Care 2022;45(1):251–254
DOI: https://doi.org/10.2337/dc21-0955
Published: 10 November 2021
View article titled, Effect of Loss-of-Function Genetic Variants in PCSK9 on Glycemic Traits, Neurocognitive Impairment, and Hepatobiliary Function
Open the PDF for Effect of Loss-of-Function Genetic Variants in PCSK9 on Glycemic Traits, Neurocognitive Impairment, and Hepatobiliary Function in another window
Journal Articles

Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression

Bruno Vergès, Laurence Duvillard, Jean Paul Pais de Barros, Benjamin Bouillet, Sabine Baillot-Rudoni, Alexia Rouland, Jean Michel Petit, Pascal Degrace, Laurent Demizieux
Journal: Diabetes Care
Diabetes Care 2021;44(4):1027–1037
DOI: https://doi.org/10.2337/dc20-1843
Published: 02 February 2021
View article titled, Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression
Open the PDF for Liraglutide Increases the Catabolism of Apolipoprotein B100–Containing Lipoproteins in Patients With Type 2 Diabetes and Reduces Proprotein Convertase Subtilisin/Kexin Type 9 Expression in another window
Journal Articles

Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial

Lawrence A. Leiter, Hwee Teoh, David Kallend, R. Scott Wright, Ulf Landmesser, Peter L.J. Wijngaard, John J.P. Kastelein, Kausik K. Ray
Journal: Diabetes Care
Diabetes Care 2019;42(1):173–176
DOI: https://doi.org/10.2337/dc18-1491
Published: 28 November 2018
View article titled, Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial
Open the PDF for Inclisiran Lowers LDL-C and PCSK9 Irrespective of Diabetes Status: The ORION-1 Randomized Clinical Trial in another window
Includes: Supplementary data
Journal Articles

Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364–367

Luiz Sérgio F. de Carvalho, Alessandra M. Campos, Andrei C. Sposito
Journal: Diabetes Care
Diabetes Care 2018;41(4):e70–e71
DOI: https://doi.org/10.2337/dci17-0069
Published: 12 March 2018
View article titled, Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364–367
Open the PDF for Response to Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364–367 in another window
Journal Articles

Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364–367

Ye-Xuan Cao, Jian-Jun Li
Journal: Diabetes Care
Diabetes Care 2018;41(4):e69
DOI: https://doi.org/10.2337/dc17-2563
Published: 12 March 2018
View article titled, Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364–367
Open the PDF for Comment on de Carvalho et al. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years. Diabetes Care 2018;41:364–367 in another window
Journal Articles

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years

Luiz Sérgio F. de Carvalho, Alessandra M. Campos, Andrei C. Sposito
Journal: Diabetes Care
Diabetes Care 2018;41(2):364–367
DOI: https://doi.org/10.2337/dc17-1464
Published: 27 November 2017
View article titled, Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years
Open the PDF for Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors and Incident Type 2 Diabetes: A Systematic Review and Meta-analysis With Over 96,000 Patient-Years in another window
Includes: Supplementary data
Journal Articles

PCSK9 Is Increased in Youth With Type 1 Diabetes

Amy E. Levenson, R. Paul Wadwa, Amy S. Shah, Philip R. Khoury, Thomas R. Kimball, Elaine M. Urbina, Sarah D. de Ferranti, Franziska K. Bishop, David M. Maahs, Lawrence M. Dolan, Sudha B. Biddinger
Journal: Diabetes Care
Diabetes Care 2017;40(7):e85–e87
DOI: https://doi.org/10.2337/dc16-2563
Published: 13 June 2017
View article titled, PCSK9 Is Increased in Youth With Type 1 Diabetes
Open the PDF for PCSK9 Is Increased in Youth With Type 1 Diabetes in another window
Journal Articles

High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients

Michele F. Eisenga, Dorien M. Zelle, John H. Sloan, Carlo A.J.M. Gaillard, Stephan J.L. Bakker, Robin P.F. Dullaart
Journal: Diabetes Care
Diabetes Care 2017;40(7):894–901
DOI: https://doi.org/10.2337/dc16-2258
Published: 01 May 2017
View article titled, High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients
Open the PDF for High Serum PCSK9 Is Associated With Increased Risk of New-Onset Diabetes After Transplantation in Renal Transplant Recipients in another window
Includes: Supplementary data